Pre-earnings options volume in Allogene Therapeutics (ALLO) is normal with puts leading calls 19:4. Implied volatility suggests the market is anticipating a move near 16.7%, or 18c, after results are released. Median move over the past eight quarters is 3.6%.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLO:
- Options Volatility and Implied Earnings Moves Today, August 13, 2025
- Is ALLO a Buy, Before Earnings?
- Strategic Adjustments and Technological Advancements Drive Buy Rating for Allogene Therapeutics
- Allogene Therapeutics: Strategic Adjustments and Positive Interim Data Justify Buy Rating
- Allogene Therapeutics downgraded to Neutral from Overweight at JPMorgan